TABLE 1.
Demographic and clinicopathologic characteristics of the 20 patients enrolled in the study
| Feature | No. of patients (N = 20) |
|---|---|
| Median age, y (range) | 68 (29‐86) |
| Sex, N (%) | |
| Male | 10 (50) |
| Female | 10 (50) |
| Smoking status, N (%) | |
| Ever | 11 (55) |
| Never | 9 (45) |
| T‐stage, N (%) | |
| 1 | 4 (20) |
| 2 | 1 (5) |
| 3 | 5 (25) |
| 4 | 10 (50) |
| N‐stage, N (%) | |
| 0 | 1 (5) |
| 1 | 3 (15) |
| 2 | 2 (10) |
| 3 | 14 (70) |
| M‐stage, N (%) | |
| 0 | 5 (25) |
| 1 | 15 (75) |
| Clinical or pathologic stage, N (%) | |
| Ⅰ | 1 (5) |
| Ⅱ | 2 (10) |
| Ⅲ | 4 (20) |
| Ⅳ | 13 (65) |
| Driver genes in tissue, N (%) | |
| ALK | 14 (70) |
| ROS1 | 4 (20) |
| RET | 2 (10) |
| Initial treatment, N (%) | |
| Operation | 3 (15) |
| Chemotherapy | 2 (10) |
| Alectinib | 10 (50) |
| Crizotinib | 3 (15) |
| Selpercatinib | 2 (10) |